Screener / SEC EDGAR /CIK 0002019410 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Caris Life Sciences, Inc. CAI

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Mar 3, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-62.4% to 5.6% (+67.9 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+97.0%

“MI Profile and Caris Assure clinical testing revenue increased year over year, driven primarily by higher reimbursement and higher clinical case volume.”

Read it in the 10-K

“Gross profit, calculated as total revenue less cost of services, was $539.2 million for the year ended December 31, 2025, compared to $178.8 million for the year ended December 31, 2024, an increase of $360.4 million, or 201.6%, primarily due to the increase in molecular profiling services revenue.”

Read it in the 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.